114 related articles for article (PubMed ID: 15860175)
1. [Abdominal pain and rectorrhage in a 68-year-old woman].
Guardiola H; Pérez Muñoz N
Med Clin (Barc); 2005 Apr; 124(15):588-94. PubMed ID: 15860175
[No Abstract] [Full Text] [Related]
2. Rituximab for treatment of advanced extranodal marginal zone B cell lymphoma of the mucosa-associated lymphoid tissue lymphoma.
Raderer M; Jäger G; Brugger S; Püspök A; Fiebiger W; Drach J; Wotherspoon A; Chott A
Oncology; 2003; 65(4):306-10. PubMed ID: 14707449
[TBL] [Abstract][Full Text] [Related]
3. Intralesional rituximab for primary iris lymphoma.
Demirci H; Grant JS; Elner VM
JAMA Ophthalmol; 2015 Jan; 133(1):104-5. PubMed ID: 25211092
[No Abstract] [Full Text] [Related]
4. Rituximab immunotherapy for ocular adnexal lymphoma: clinicopathologic correlation with 5-year follow-up.
Sokol JA; Landau L; Lauer SA
Ophthalmic Plast Reconstr Surg; 2009; 25(4):322-4. PubMed ID: 19617799
[TBL] [Abstract][Full Text] [Related]
5. Treatment of localized oral MALT lymphoma by rituximab: a case report.
Yamagata K; Onizawa K; Kojima H; Yoshida H
Oral Maxillofac Surg; 2008 Dec; 12(4):227-30. PubMed ID: 18830723
[TBL] [Abstract][Full Text] [Related]
6. Phase II trial evaluating the efficacy and safety of the anti-CD20 monoclonal antibody obinutuzumab in patients with marginal zone lymphoma.
Grunenberg A; Kaiser LM; Woelfle S; Schmelzle B; Viardot A; Möller P; Barth TF; Muche R; Dreyhaupt J; Buske C
Future Oncol; 2020 May; 16(13):817-825. PubMed ID: 32223334
[TBL] [Abstract][Full Text] [Related]
7. Treatment of splenic marginal zone lymphoma: splenectomy versus rituximab.
Bennett M; Schechter GP
Semin Hematol; 2010 Apr; 47(2):143-7. PubMed ID: 20350661
[TBL] [Abstract][Full Text] [Related]
8. Diagnostic and therapeutic challenges.
Cantrill HL; Pulido JS; Donaldson M; Shields CL; Murray TG
Retina; 2008; 28(7):1018-22. PubMed ID: 18698308
[No Abstract] [Full Text] [Related]
9. Rituximab for the treatment of extranodal marginal zone B-cell lymphoma of the lacrimal gland.
Heinz C; Merz H; Nieschalk M; Mueller-Miny H; Koch P; Heiligenhaus A
Br J Ophthalmol; 2007 Nov; 91(11):1563-4. PubMed ID: 17947275
[No Abstract] [Full Text] [Related]
10. [Clinical observation of Rituximab in a CD20+B non-Hodgkin's lymphoma].
Hao LC; Zhang LZ
Zhonghua Er Ke Za Zhi; 2003 Aug; 41(8):627. PubMed ID: 14744396
[No Abstract] [Full Text] [Related]
11. Clonal selection of CD20-negative non-Hodgkin's lymphoma cells after treatment with anti-CD20 antibody rituximab.
Schmitz K; Brugger W; Weiss B; Kaiserling E; Kanz L
Br J Haematol; 1999 Aug; 106(2):571-2. PubMed ID: 10460626
[No Abstract] [Full Text] [Related]
12. Extended rituximab schedules may result in increased efficacy in pulmonary malt lymphoma.
Seker M; Bilici A; Ustaalioglu BO; Salman T; Sonmez B; Canpolat NA; Salepci T; Gumus M; Yaylaci M
Leuk Res; 2009 Sep; 33(9):e154-6. PubMed ID: 19386361
[No Abstract] [Full Text] [Related]
13. Intestinal lymphoma perforations as a consequence of highly effective anti-CD20 antibody therapy.
Kollmar O; Becker S; Schilling MK; Maurer CA
Transplantation; 2002 Feb; 73(4):669-70. PubMed ID: 11889454
[No Abstract] [Full Text] [Related]
14. Intralesional rituximab: a new therapeutic approach for patients with conjunctival lymphomas.
Ferreri AJ; Govi S; Colucci A; Crocchiolo R; Modorati G
Ophthalmology; 2011 Jan; 118(1):24-8. PubMed ID: 20709407
[TBL] [Abstract][Full Text] [Related]
15. Transformation of MALT lymphoma to pure plasma cell histology: possible association with anti-CD20 antibody treatment.
Klein N; Elis A; Radnay J; Zemer R; Klein A; Lishner M
Isr Med Assoc J; 2009 Nov; 11(11):703-4. PubMed ID: 20108563
[No Abstract] [Full Text] [Related]
16. Recurrence of IgG4-related disease following treatment with rituximab.
Murakami J; Matsui S; Ishizawa S; Arita K; Wada A; Miyazono T; Hounoki H; Shinoda K; Taki H; Sugiyama T
Mod Rheumatol; 2013 Nov; 23(6):1226-30. PubMed ID: 22956241
[TBL] [Abstract][Full Text] [Related]
17. Rituximab immunotherapy for non-Hodgkin's lymphoma.
White CA
Cancer Biother Radiopharm; 1999 Aug; 14(4):241-50. PubMed ID: 10850310
[TBL] [Abstract][Full Text] [Related]
18. Acquired C1 esterase inhibitor deficiency in a marginal zone lymphoma patient treated with rituximab.
Ates O; Sunar V; Babacan T; Akin S; Kertmen N; Altundag K
J BUON; 2015; 20(1):349. PubMed ID: 25778339
[No Abstract] [Full Text] [Related]
19. [Radioimmunotherapy for B-cell lymphoma].
Tobinai K
Rinsho Ketsueki; 2006 Jun; 47(6):463-70. PubMed ID: 16862974
[No Abstract] [Full Text] [Related]
20. Primary breast mucosa-associated lymphoid tissue (MALT) lymphoma with high-grade transformation evidenced by prominent lymphoepithelial lesions.
Taeda Y; Ariga N; Okamura K; Takei N; Komeno T; Ueki H; Ohtani H
Breast Cancer; 2006; 13(3):322-327. PubMed ID: 16929129
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]